Transdermal radiofrequency (V ERASER®) plus polidocanol sclerotherapy versus polidocanol sclerotherapy alone for the treatment of reticular veins and telangiectasias. A randomized controlled trial (TYPER trial)

Rebeca Higino Becker, Roberto Augusto Caffaro, Caroline Cândida Carvalho de Oliveira, Rafaela Palermo Marcondes, Ariadne Ribeiro Negrão, Flávia Magella, Giuliano Giova Volpiani, Samantha Neves, Renata Camila Barros Rodrigues, Mariana Ferreira Borges Firmo Rodrigues, Viviane Santana da Silva, Camilla Moreira Ribeiro, Rodrigo Kikuchi, Fabricio Rodrigues Santiago, Eduardo Ramacciotti, Vascular Surgery Department, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Vascular Surgery Department, Centro Universitário São Lucas Ji-Paraná, Vascular Surgery Department, Universidade do Rio Grande , Rio Grande, Rio Grande do Sul, Clinical Trials Department, Science Valley Research Institute, São Paulo, Vascular Surgery Department, Universidade Federal de Goiás, Thrombosis Research Laboratories, Loyola University Medical Centre

Phlebology: The Journal of Venous Disease

Published online on September 04, 2025

Abstract

Phlebology, Volume 41, Issue 5, Page 410-418, June 2026.
BackgroundSclerotherapy with polidocanol is the gold standard treatment for telangiectasias and varicose veins, but technologies such as transdermal radiofrequency are also available. Transdermal radiofrequency (V Eraser®), a device that combines ...